Ultragenyx Pharmaceutical Inc Revenue Growth Rates (RARE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ultragenyx Pharmaceutical Inc   (NASDAQ: RARE)
 

RARE's Revenue Growth by Quarter and Year

Ultragenyx Pharmaceutical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RARE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 214.00
1st Quarter March 136.00
FY 350.00

RAREs Annual Revenue
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2025 $ 673.00 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2024 $ 560.23 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2023 $ 434.25 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2022 $ 363.33 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2021 $ 351.41 millions




RARE Revenue second quarter 2026 Y/Y Growth Comment
Ultragenyx Pharmaceutical Inc reported Revenue improvement of 28.53% year on year in the second quarter 2026, to $ 214.00 millions, this is lower than Ultragenyx Pharmaceutical Inc 's recent average Revenue rise of 57.61%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Ultragenyx Pharmaceutical Inc ' s Revenue rise of 28.53% ranks overall at the positon no. 2016 in the second quarter 2026.


RARE Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 25.72 % 29.43 % 23.26 %
3rd Quarter September - 14.65 % 42.26 % 8.1 %
2nd Quarter June 28.53 % 13.24 % 35.75 % 21.23 %
1st Quarter March -2.36 % 27.99 % 8.29 % 25.72 %
FY   - 20.13 % 29.01 % -

Financial Statements
Ultragenyx Pharmaceutical Inc 's second quarter 2026 Revenue $ 214.00 millions RARE's Income Statement
Ultragenyx Pharmaceutical Inc 's second quarter 2025 Revenue $ 166.50 millions Quarterly RARE's Income Statement


RARE Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 29.61 % 18.2 % 29.92 %
3rd Quarter September - -3.95 % -5.13 % -9.47 %
2nd Quarter June 57.35 % 19.53 % 35.1 % 7.77 %
1st Quarter March -34.39 % -15.52 % -14.57 % -2.76 %
FY (Year on Year)   - 20.13 % 29.01 % -


Back to RARE Growth rate Comparisons >> Back to RARE Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #310
Overall #2016

Revenue Y/Y Growth Statistics
High Average Low
174.2 % 57.61 % -6.98 %
(Mar 31 2021)   (Jun 30 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #310
Overall #2016
Revenue Y/Y Growth Statistics
High Average Low
174.2 % 57.61 % -6.98 %
(Mar 31 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ultragenyx Pharmaceutical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1119.19 % 57.94 % -100 %
(Dec 31 2017)  


RARE's II. Quarter Q/Q Revenue Comment
Ultragenyx Pharmaceutical Inc achieved in the II. Quarter 2026 below company average Revenue jump of 57.35% quarter on quarter, to $ 214.00 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 19.53% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Ultragenyx Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 215.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #215
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #215
Revenue Q/Q Growth Statistics
High Average Low
1119.19 % 57.94 % -100 %
(Dec 31 2017)  


RARE's II. Quarter Q/Q Revenue Comment
Ultragenyx Pharmaceutical Inc achieved in the II. Quarter 2026 below company average Revenue jump of 57.35% quarter on quarter, to $ 214.00 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 19.53% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Ultragenyx Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 215.


Ultragenyx Pharmaceutical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 717.21 $ 669.71 $ 673.00 $ 630.60 $ 610.16
Y / Y Revenue Growth (TTM) 17.55 % 13.38 % 20.13 % 20.63 % 26.77 %
Year on Year Revenue Growth Overall Ranking # 637 # 399 # 259 # 322 # 586
Seqeuential Revenue Change (TTM) 7.09 % -0.49 % 6.72 % 3.35 % 3.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 2275 # 1727 # 1105 # 973 # 1190


Cumulative Revenue growth Comment
Although Ultragenyx Pharmaceutical Inc 's Annual Revenue growth year on year were below company's average 56.23% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.55% year on year, from 13.38% in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 399 to 637.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
174.2 %
 56.23 %
-6.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 330
S&P 500 # 2275
Cumulative Revenue growth Comment
Although Ultragenyx Pharmaceutical Inc 's Annual Revenue growth year on year were below company's average 56.23% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.55% year on year, from 13.38% in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 399 to 637.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
174.2 %
56.23 %
-6.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 330
S&P 500 # 2275




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RARE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions


About Ultragenyx Pharmaceutical Inc Revenue Growth Rates (RARE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ultragenyx Pharmaceutical Inc (CIK 1515673).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-333233
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ultragenyx Pharmaceutical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.